A Case of Ganciclovir-resistant CMV Antigenemia by UL97 Phosphotransferase Mutant Strain after Cord Blood Transplantation.
- Author:
Young Shil PARK
1
;
Yun Suk JEON
;
Bin CHO
;
Nak Gyun CHUNG
;
Dong Gun LEE
;
Su Mi CHOI
;
Wan Shik SHIN
;
Hack Ki KIM
Author Information
1. Department of Pediatrics, The Catholic University of Korea, College of Medicine, Seoul, Korea. cngped@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Cytomegalovirus;
Resistance;
Antivirals;
UL97
- MeSH:
Antiviral Agents;
Codon;
Cytomegalovirus;
Fetal Blood*;
Ganciclovir;
Hematopoietic Stem Cell Transplantation;
Humans;
Immunosuppressive Agents
- From:Korean Journal of Pediatric Hematology-Oncology
2004;11(2):265-270
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Despite the availability of effective antiviral drugs, human cytomegalovirus (CMV) infection is still a serious life-threatening complication in recipients of allogeneic hematopoietic stem cell transplantation. Ganciclovir (GCV) preemptive therapy is currently the usual treatment for CMV disease and antigenemia. However, prolonged GCV therapy results in the emergence of drug-resistant virus. Most GCV-resistant clinical CMV isolates contain a mutation in the UL97 phosphotransferase gene. We report a case that GCV-resistant CMV antigenemia by UL97 phosphotransferase mutant strain at codon 460 and 605 which was improved by reduction of immunosuppressants for posttransplant lymphoproliferative disease after unrelated cord blood transplantation.
